53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Authored by Hyfe's R&D team, this review synthesizes work presented at the European Respiratory Society Congress 2025 and argues that objective cough monitoring has crossed a practical threshold, moving from experimental technique to deployable clinical endpoint.
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
This study asked whether the core components of BCST could be embedded in a digital therapeutic and paired with continuous, objective cough monitoring inside the CoughPro app.
Authored by Hyfe's R&D team, this review synthesizes work presented at the European Respiratory Society Congress 2025 and argues that objective cough monitoring has crossed a practical threshold, moving from experimental technique to deployable clinical endpoint.
Validated algorithms across smartwatches, chest patches, pendants, and audio recorders now show strong agreement with human annotation (sensitivities of 90 to 97%) across refractory chronic cough, COPD, IPF, ILD, and asthma. The review also covers convergence on a 7-day monitoring standard, device-verified adherence at scale, and early efficacy and tolerability signals from interventional trials using continuous cough endpoints. The authors conclude that cough is transitioning from a background symptom to a quantifiable data stream ready to support precision respiratory care across therapeutic areas.
